Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biohit Oyj Announces Preliminary Results on Clinical Study and Continues Clinical Study to Determine Capacity of BioAcetium Product to Treat Helicobacter Pylori Infection


Tuesday, 29 Jan 2013 02:30am EST 

Biohit Oyj announced that it has received the preliminary results on the clinical study, the purpose of which is to determine the capacity of the new BioAcetium product to eradicate Helicobacter pylori infection. Based on the results, Biohit Oyj has decided to conduct further examinations that will use longer treatment times. In further examinations BioAcetium will also be combined with an antibiotic that does not cause development of antibiotic-resistant strains of the bacteria. The clinical study was conducted in cooperation with HUS Gastroenterology clinic (Hospital District of Helsinki and Uusimaa) and GastroLaakarit. The purpose of the study was to determine the new BioAcetium ability to treat Helicobacter pylori in individuals over 55 years of age who have not been diagnosed with a prior H. pylori infection. 

Company Quote

4.71
0.03 +0.64%
23 Dec 2014